Active Development. Notwithstanding anything herein to the contrary, Celgene’s exclusivity (including any […***…]), rights and licenses will expire with respect to a Collaboration Sequence Pair if Celgene ceases active research and development of the Antibody generated from and incorporating such Collaboration Sequence Pair or Product(s) incorporating such Antibody.
Appears in 2 contracts
Sources: Collaboration Agreement (Zymeworks Inc.), Collaboration Agreement (Zymeworks Inc.)